top of page
Sync Up

About us

Our story

 

Biomedical Bonding (BMB) is a Swedish MedTech company that develops cutting-edge medical adhesive fixators and novel surgical methodologies. BMB is a spinout company from Royal Institute of Technology in Stockholm and was founded by Professor Michael Malkoch. The adhesive platform is based on more than a decade of intensive academic research.

BMB wants to overcome the current pain points in today’s bone fracture surgery and dental restorations by introducing a unique technology platform based on a novel category of adhesive resin-composites with focus on biocompatibility, tissue-friendliness and high mechanical strength.

BMB has been funded by Vinnova and EU Horizon 2020 to continue the development together with e.g. Karolinska Institute, RISE (Research Institutes of Sweden), AO Research Institute Davos as well as surgeons from Stockholm South General Hospital (SÖS) and Hvidovre Hospital to reach the threshold for commercialization.

 

BMB has worked towards making the technology available for clinical use and is now ready to commercialize products with the ambition to improve treatments and enhance patient’s life quality.

Financial Graphs

"BMB has its optics focused on challenging the current standard-of-care implantable metal fixators for fracture treatments. As no competitive technology exists on the market, BMB’s Bonevolent™ platform will be the first mover by providing patient-personalized composite-based fixators that enhances the patient’s ability to recover, independent if it is for human or animal wellbeing."

Michael Malkoch
Founder 
bottom of page